Swiss-based Novartis is partnering with a Californian startup called Science 37 to try a new technology the companies hope will boost clinical trial participation.
For 10 trials over three years, the companies will employ a mobile technology that will allow patients to stay involved in the study remotely. Costly and time-consuming visits to clinics is a common barrier for patients hoping to be involved in clinical trials, and is the main reason why Novartis estimates that just 2 percent of the U.S. population joins them.
Science 37 says that its mobile technology platform brings “research directly to patients in their homes through telemedicine.”
Novartis has reported in the past that it plans to use new tech tools to cut the costs of R&D.
Read the full Reuters report.